WANG, YA FANG,王雅芳,王雅芳,WANG, JEN REN,王贞仁,王貞仁,CHEN, YI HSING,陈奕兴,陳奕興
申请号：
TW102141587
公开号：
TWI505831B
申请日:
2013.11.15
申请国别(地区):
TW
年份:
2015
代理人:
摘要：
The present invention relates to a composition used for treating picornavirus infection comprising at least one of the following bacterial strains:Lactobacillus paracaseiGMNL-33 with the deposition numbers of BCRC 910314(CCTCC M 206133),Lactobacillus reuteriGMNL-89 with the deposition numbers of BCRC 910340(CCTCC M 207154) andLactobacillus caseiGMNL-277 with the deposition numbers of BCRC 910585(CCTCC M 2013197), and a pharmaceutically acceptable vehicle. TheLactobacillus caseiGMNL-277 of the invention is a novelLactobacillusisolated strain. In addition, the present invention also features the novel use of the composition or theLactobacillusstrains for treating picornavirus infection, and the mechanism of which is inhibition of virus infection by binding of the probiotic bacteria to viruses.本發明係一種治療微小核糖核酸病毒感染的組合物,其包含副乾酪乳桿菌(GMNL-33)之寄存編號為BCRC 910314(CCTCC M 206133)、羅伊氏乳桿菌(GMNL-89)之寄存編號為BCRC 910340(CCTCC M 207154)及乾酪乳桿菌(GMNL-277)其寄存編號為BCRC 910585(CCTCC M 2013197)至少一種,及藥學上可接受之載劑。其中該乾酪乳桿菌GMNL-277為新穎乳桿菌分離株。另,本發明亦關於藉由該組合物或該乳桿菌用以治療微小核糖核酸病毒感染之新穎用途,其作用機制為益生菌株與病毒結合,而降低病毒感染細胞之能力。
